ArticleNature microbiology2022
Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern.
Article in Nature microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 56 citations in OpenAlex.
- Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2-18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study.The Lancet. Infectious diseases · 2022Trial
- Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants.Scientific reports · 2022Trial
- Adsorption of antigen to polymeric nanoparticles enhances cytotoxic T-cell responses and anti-tumor immunity by targeting conventional type 1 dendritic cells.Immunology and cell biology · 2025Article
- Essential role of CD56Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Human T Cell Responses to Flavivirus Vaccines.European journal of immunology · 2025Review
- Review
- Role of antiviral CD8+ T cell immunity to SARS-CoV-2 infection and vaccination.Journal of virology · 2025Review
- A Comprehensive Review of mRNA-based Vaccines for COVID-19, A New Era in Pharmaceuticals: Unspecified and Unknown Aspects, Effects and Challenges.Current topics in medicinal chemistry · 2025Review
- Vaccination with inactivated SARS-CoV-2 vaccine TURKOVAC induces durable humoral and cellular immune responses up to 8 months.Frontiers in medicine · 2025Article
- Humoral and cellular immune response to AZD1222 /Covishield and BV152/Covaxin COVID-19 vaccines among adults in India.Human vaccines & immunotherapeutics · 2024Article
- Review
- Precision adjuvants for pediatric vaccines.Science translational medicine · 2024Review
- T-B coculture assay for functional analysis of antigen-specific memory CD4STAR protocols · 2024Article
- Immune profiling of age and adjuvant-specific activation of human blood mononuclear cells in vitro.Communications biology · 2024Article
- Article
- Article
- An Overview of SARS-CoV-2 Etiopathogenesis and Recent Developments in COVID-19 Vaccines.Biomolecules · 2023Review
- Polyfunctional CD4 T-cells correlating with neutralising antibody is a hallmark of COVISHIELDNPJ vaccines · 2023Article
- Impact of E484Q and L452R Mutations on Structure and Binding Behavior of SARS-CoV-2 B.1.617.1 Using Deep Learning AlphaFold2, Molecular Docking and Dynamics Simulation.International journal of molecular sciences · 2023Article
- SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines.Vaccines · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 6 institutions in 2 countries.
Funding
Abstract
BBV152 is a whole-virion inactivated vaccine based on the Asp614Gly variant. BBV152 is the first alum-imidazoquinolin-adjuvanted vaccine authorized for use in large populations. Here we characterized the magnitude, quality and persistence of cellular and humoral memory responses up to 6 months post vaccination. We report that the magnitude of vaccine-induced spike and nucleoprotein antibodies was comparable with that produced after infection. Receptor binding domain-specific antibodies declined against variants in the order of Alpha (B.1.1.7; 3-fold), Delta (B.1.617.2; 7-fold) and Beta (B.1.351; 10-fold). However, pseudovirus neutralizing antibodies declined up to 2-fold against the Delta followed by the Beta variant (1.7-fold). Vaccine-induced memory B cells were also affected by the Delta and Beta variants. The SARS-CoV-2-specific multicytokine-expressing CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.